Loading
A phase 3 trial of Acalabrutinib, Venetoclax and Obinutuzumab in chronic lymphocytic leukaemia, run by AstraZeneca, active and no longer recruiting.
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma is a phase 3 interventional study registered as NCT05057494 by AstraZeneca, with 607 participants enrolled, started 2022-09-12 and due to reach its primary completion in 2027-07-15. Interventions recorded: Acalabrutinib, Venetoclax and Obinutuzumab.
Shares Acalabrutinib, BCL-2 inhibitors, Obinutuzumab, Chronic lymphocytic leukaemia, first treatment and the tag pipeline.
Shares BCL-2 inhibitors, Obinutuzumab, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Acalabrutinib, BCL-2 inhibitors, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Acalabrutinib, BCL-2 inhibitors, Chronic lymphocytic leukaemia, first treatment, Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, Chronic lymphocytic leukaemia, first treatment, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Acalabrutinib, Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia, AstraZeneca and the tag pipeline.
Shares BCL-2 inhibitors, Obinutuzumab, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.